Cargando…

Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies

Glioblastoma is the most common and aggressive malignant tumor of the central nervous system. Despite the existing high unmet medical needs, the past few decades have seen no notable improvement in overall survival for glioblastoma patients. One active area of research to develop new therapeutic opt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krendyukov, Andriy, Gieffers, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6730539/ https://www.ncbi.nlm.nih.gov/pubmed/31564969 http://dx.doi.org/10.2147/CMAR.S216675

Ejemplares similares

Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
por: Wick, Wolfgang, et al.
Publicado: (2019)

Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile
por: Radujkovic, Aleksandar, et al.
Publicado: (2020)

CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
por: Richards, David M, et al.
Publicado: (2021)

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
por: Hanke, Nina, et al.
Publicado: (2019)

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
por: Wei, Kuo-Chen, et al.
Publicado: (2021)

Innovative oncology products: time to revisit the strategy development?
por: Krendyukov, Andriy
Publicado: (2019)

Early Access Provision for Innovative Medicinal Products in Oncology: Challenges and Opportunities
por: Krendyukov, Andriy
Publicado: (2020)

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
por: Dellanna, Frank, et al.
Publicado: (2017)

Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018)

The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
por: Schiestl, Martin, et al.
Publicado: (2017)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Glioblastoma Multiforme: Novel Therapeutic Approaches
por: Fialho, Arsenio M., et al.
Publicado: (2012)

Development and 10-year history of a biosimilar: the example of Binocrit(®)
por: Aapro, Matti, et al.
Publicado: (2018)

Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma
por: Dolgova, Evgeniya V., et al.
Publicado: (2021)

Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
por: Fortunato, Fernanda, et al.
Publicado: (2021)

Is Glioblastoma an Epigenetic Malignancy?
por: Maleszewska, Marta, et al.
Publicado: (2013)

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019)

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
por: Krendyukov, Andriy, et al.
Publicado: (2021)

MTAP loss: a possible therapeutic approach for glioblastoma
por: Patro, C. Pawan K., et al.
Publicado: (2022)

Therapeutic strategies of recurrent glioblastoma and its molecular pathways ‘Lock up the beast’
por: El-khayat, Shaimaa M, et al.
Publicado: (2021)

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers
por: Sahin, Ilyas, et al.
Publicado: (2021)

Innovative Therapies against Human Glioblastoma Multiforme
por: Cimini, Annamaria, et al.
Publicado: (2011)

Biological Characterization and Therapeutics for Subscalp Recurrent in Intracranial Glioblastoma
por: Zhang, Junwen, et al.
Publicado: (2020)

Innovative Therapeutic Approaches Based on Nanotechnology for the Treatment and Management of Tuberculosis
por: Kia, Pooneh, et al.
Publicado: (2023)

Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study
por: Aapro, Matti, et al.
Publicado: (2019)

Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors
por: Nemes, Karolina, et al.
Publicado: (2022)

Glioblastoma multiforme: Effect of hypoxia and hypoxia inducible factors on therapeutic approaches
por: Huang, Wen-Juan, et al.
Publicado: (2016)

Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles
por: Boltman, Taahirah, et al.
Publicado: (2023)

New therapies for recurrent glioblastomas
por: Wen, Patrick Y
Publicado: (2009)

Interdisciplinary Therapeutic Approaches to Atypical and Malignant Meningiomas
por: Trakolis, Leonidas, et al.
Publicado: (2023)

The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
por: Liu, Xudong, et al.
Publicado: (2023)

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer
por: Krendyukov, A., et al.
Publicado: (2017)

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
por: Strobel, Hannah, et al.
Publicado: (2019)

Radiosensitization and Radioprotection by Curcumin in Glioblastoma and Other Cancers
por: Zoi, Vasiliki, et al.
Publicado: (2022)

Early access provision: Awareness, educational needs and opportunities to improve oncology patients’ access to care
por: Krendyukov, Andriy, et al.
Publicado: (2022)

T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2021)

Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches
por: Cabaud-Gibouin, Vincent, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qcblp00q817jbj8lpg0p97b30b